NEW YORK – AiCure’s artificial intelligence platform led to a 50% improvement in medication adherence for stroke patients, a recent study has found.
“In the absence of routine laboratory monitoring, artificial intelligence has the potential to automate a critical component of care—adherence monitoring—and provide continuity of care between visits to ensure patients persist with their therapy and get full therapeutic benefit,” said Dr. Daniel Labovitz, lead author of a paper on the study and director of the Stern Stroke Center at Montefiore Medical Center, in a statement.
The 12-week study included ischemic stroke survivors randomly assigned to the AI platform for daily monitoring or treatment as usual groups. To measure treatment adherence, researchers tested the concentration of medication in blood samples. Blood tests showed that 100% of patients in the intervention arm took medication regularly, compared to only half in the control arm.
The AiCure platform uses software algorithms on smartphones to automatically confirm patient identity, the medication and ingestion. In addition, patients receive automated reminders and precise dosing instructions, and healthcare workers can review real-time data. Early detection of non-adherence allowed for immediate follow up and ensured patients stayed on track in the intervention group.
The study demonstrated that patients with little prior experience using a smartphone were able to easily learn how to use the technology and use it consistently, said Labovitz.